Clincosm LogoSign in Get a demo

Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients

Sponsor
Arrowhead Regional Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT05964088
Collaborator
(none)
267
Enrollment
1
Location
23.4
Actual Duration (Months)
11.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study explored the incidence of morbidity and mortality associated with AKI in critically ill adult patients infected with COVID-19. There are two groups for comparison. Group1. patients were directly admitted to the intensive care unit (ICU) from the emergency department (ED) Group 2. patients were initially managed on the medical floor and later transferred to the ICU for worsening respiratory status. The investigating team evaluated the correlation of inflammatory markers and common risk factors such as obesity, diabetes, hypertension and ethnicity to the development of AKI in the target population. The primary outcome is mortality participants will received their regular healthcare in a medical setting

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    267 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients
    Actual Study Start Date :
    Mar 1, 2020
    Actual Primary Completion Date :
    Feb 12, 2022
    Actual Study Completion Date :
    Feb 12, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Group1

    These critically ill patients were directly admitted to the intensive care unit from the emergency department
    Group 2

    These critically ill patients were were initially managed on the medical floor and later transferred to the intensive care unit for worsening respiratory status

    Outcome Measures

    Primary Outcome Measures

    1. Mortality [from admission until death from any cause, whichever comes first, assessed up to three months]

      mortality at hospital discharge

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 100 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    positive for SARS-CoV-2 on a real-time polymerase chain reaction test (RT-PCR) upon admission to the hospital

    Exclusion Criteria:

    chronic kidney disease end stage renal disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Arrowhead Regional Medical Center Colton California United States 92324

    Sponsors and Collaborators

    • Arrowhead Regional Medical Center

    Investigators

    • Principal Investigator: Michael M Neeki, DO, Arrowhead Regional Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michael Neeki, Attending Physician, Arrowhead Regional Medical Center
    ClinicalTrials.gov Identifier:
    NCT05964088
    Other Study ID Numbers:
    • 22-18
    First Posted:
    Jul 27, 2023
    Last Update Posted:
    Jul 27, 2023
    Last Verified:
    Jul 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Acute Kidney Injury
    Wounds and Injuries

    Study Results

    No Results Posted as of Jul 27, 2023